GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.
Also called NCT06003153
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT06003153
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06003153. Allocation not applicable; no masking; primary purpose treatment. Start 2024-03-12 (actual); primary completion 2027-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
- Acronym
- GLUCOSE-MGH
- Condition
- Genetic Predisposition
- Condition
- Metabolic Diseases
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- oral semaglutide
- Intervention (Other)
- Mixed Meal Tolerance Test (MMTT)
- Lead sponsor
- Massachusetts General Hospital
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct06003153- Content hash
43167cabbcccb76fea3f2f9494a86ee2a53e5333f30b039f8547d3bbedf884ad